10X Genomics Inc

NASDAQ TXG

Download Data

10X Genomics Inc Equity to Assets Ratio 2 year CAGR for the quarter ending March 31, 2024: -1.58%

10X Genomics Inc Equity to Assets Ratio 2 year CAGR is -1.58% for the quarter ending March 31, 2024, a -1,070.69% change year over year. The Equity to Assets Ratio measures the proportion of a company's total assets that are financed by equity. It provides insight into the company's financial stability and the percentage of assets owned by shareholders. A higher ratio indicates a greater ownership stake by equity shareholders and suggests lower financial risk. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • 10X Genomics Inc Equity to Assets Ratio for the quarter ending March 31, 2023 was 0.79, a -1.59% change year over year.
  • 10X Genomics Inc Equity to Assets Ratio for the quarter ending March 31, 2022 was 0.80, a 1.95% change year over year.
  • 10X Genomics Inc Equity to Assets Ratio for the quarter ending March 31, 2021 was 0.79, a 17.69% change year over year.
  • 10X Genomics Inc Equity to Assets Ratio for the quarter ending March 31, 2020 was 0.67.
NASDAQ: TXG

10X Genomics Inc

CEO Dr. Serge Saxonov Ph.D.
IPO Date Sept. 12, 2019
Location United States
Headquarters 6230 Stoneridge Mall Road, Pleasanton, CA, United States, 94588-3260
Employees 1,259
Sector Healthcare
Industry Health information services
Description

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Similar companies

TWST

Twist Bioscience Corp

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email